Compare Viatris Inc (VTRS) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Wynn Resorts, Limited — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Wynn Resorts, Limited trades at $90.11 (market cap $9.50B). The key difference: Viatris Inc is far larger — about 2× Wynn Resorts, Limited's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| VTRS | WYNN | |
|---|---|---|
Market Cap | $19.09B | $9.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.86 | $133.34 |
52-Week Low | $9.49 | $90.23 |
Enterprise Value | $31.21B | $19.74B |
Dividend Yield | 2.89% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, with a bearish technical signal and mixed earnings. Q2 2026 EPS beat estimates at $1.24, but Q4 2025 and Q1 2026 missed. Revenue reached $7.14B in 2025, with net income margin at 6.06%. Recent news highlights Macau strength offset by U.S. margin pressure and rising capital expenditures for new projects.
Outlook: Analyst consensus is bullish with a $132.44 price target, but risks include high debt ($10.5B long-term), profit margin compression, and significant capital spending. The stock offers growth potential from Macau recovery and new developments, yet faces headwinds from operational costs and leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
